ALS

$3B+
Global Research Spending
30K
Americans Living with ALS
2--5
Years After Diagnosis (Median)
None
Cure or Reversal

Underfunded and Relentless

ALS kills motor neurons. Muscles atrophy. Patients become paralyzed. Death from respiratory failure. Approximately 30,000 Americans live with ALS at any given time. The average survival time is 2 to 5 years after diagnosis. About $3 billion has been spent on research globally. No cure exists. Riluzole, approved in 1995, extends life by 2 to 3 months. Edaravone, approved in 2017, marginally slows decline. These are symptom management drugs, not disease-modifying therapies.

The Ice Bucket Challenge in 2014 raised $220 million for ALS research in four months. The largest single fundraising event in history for a single disease. That sum has not been replicated. Research funding remains limited relative to disease burden. The disease remains fatal and incurable.

ALS Identified (Charcot) 1869
Riluzole Approved 1995
Edaravone Approved 2017
Ice Bucket Challenge Fundraising $220M (2014)
Cures or Reversals Achieved 0

The Promise vs. Reality Pattern

1869
Discovery: Jean-Martin Charcot describes amyotrophic lateral sclerosis. Motor neuron disease. Fatal. Cause unknown.
1939
Famous Case: Lou Gehrig diagnosed. ALS becomes known as Lou Gehrig's disease. Public awareness increases. Still no treatment.
1993
SOD1 Discovery: First gene linked to familial ALS. Genetic understanding begins. Cure remains distant.
1995
Riluzole: First drug approved. Extends survival by 2--3 months. Called a milestone. Still not a cure.
2014
Ice Bucket Challenge: $220 million raised in four months. Record fundraising. New research accelerates. No cure appears.
2023
Tofersen Approval: SOD1-targeted antisense therapy approved. Slows decline in SOD1 mutations. Applies to 2% of ALS cases. Most patients unaffected.

Current Research Status

ALS research has identified dozens of genes associated with the disease. Genetic heterogeneity complicates therapy development. Each gene may require its own treatment. SOD1-targeted therapy (Tofersen) represents proof-of-concept that gene-specific therapies work. But it helps only patients with SOD1 mutations, roughly 2 percent of the ALS population. C9orf72, FUS, and TDP-43 therapies are in development. Most ALS patients have no identified genetic cause. For them, no targeted therapy exists.

Active Clinical Trials 100+
Genes Associated with ALS 30+
Tofersen-Eligible Patients (SOD1) 2%
Disease-Modifying Approvals 1 (SOD1-only)
Average Survival Extension (Best Case) 6 months

What This Means: ALS research has moved from general approaches to genetic targeting. Tofersen represents a genuine advance for a subset of patients. Most ALS patients remain without specific therapies. Riluzole and Edaravone provide marginal benefit. Palliative care remains the standard. Gene therapy and stem cell approaches show promise in research. Cure has not been achieved. Cure remains distant for all but theoretical.

Sources & Methodology

Data compiled from NIH, ALS Association, peer-reviewed sources, and clinical trial data.

Primary Sources

  • National Institutes of Health -- ALS Research Funding (RePORT Database)
  • ALS Association -- ALS Statistics and Research Overview (2023--2024)
  • ClinicalTrials.gov -- ALS Active Trials (100+ registered)
  • FDA Center for Drug Evaluation -- ALS Drug Approvals (Riluzole, Edaravone, Tofersen)
  • The Lancet Neurology -- ALS Genetic and Therapeutic Advances (2023)
  • Nature Neuroscience -- SOD1 Therapy Development and Clinical Outcomes (2023)
  • Neurology Today -- Ice Bucket Challenge Impact on ALS Research Funding (2023)